Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 8, 2025 • 5:00 AM ET

Date/Time Source News Release
05/07/2025 07:00 AM EDT GlobeNewswire Amarin Reports First Quarter 2025 Financial Results
04/29/2025 04:15 PM EDT GlobeNewswire Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
04/28/2025 04:15 PM EDT GlobeNewswire Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
04/09/2025 07:30 AM EDT GlobeNewswire Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
04/07/2025 07:30 AM EDT GlobeNewswire Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors
03/31/2025 08:00 AM EDT GlobeNewswire Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
03/12/2025 07:01 AM EDT GlobeNewswire Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
03/12/2025 07:00 AM EDT GlobeNewswire Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action 
02/27/2025 09:00 AM EST GlobeNewswire Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
02/25/2025 08:00 AM EST GlobeNewswire Amarin Receives National Reimbursement for VAZKEPA® in Austria
Page